Toward a redefinition of Parkinson's disease

Movement Disorders

Volumn 27, Issue 1, 2012, Pages 54-60

  Stern, Matthew B ^a   Lang, Anthony ^b   Poewe, Werner ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; DOPAMINE; DOPAMINE TRANSPORTER; LEVODOPA; MOLECULAR MARKER;

ALZHEIMER DISEASE; BRADYKINESIA; BRAIN ATROPHY; BRAIN REGION; CLINICAL FEATURE; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE MARKER; DYSAUTONOMIA; GENE MUTATION; HUMAN; HUNTINGTON CHOREA; MILD COGNITIVE IMPAIRMENT; MOTOR DYSFUNCTION; NEUROIMAGING; NEUROPATHOLOGY; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUBSTANTIA NIGRA; SUBSTANTIA NIGRA PARS COMPACTA; TREMOR;

DISEASE PROGRESSION; HUMANS; PARKINSON DISEASE;

EID: 84855925916     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.24051     Document Type: Note

References (65)

1. Parkinson J. An Essay on Shaking Palsy. London: Whitington and Rowland for Sherwood, Neely and Jones; 1817.
2. Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology. 1992; 42: 1142-1146.
3. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on aging and the Alzheimer's Association workgroup. Alzheimers Dement. 2011; 7: 1-7.
4. Siderowf A, Stern MB. Premotor Parkinson's disease: clinical features, detection, and prospects for treatment. Ann Neurol. 2008; 64( Suppl 2): S139-S147.
5. Siderowf A, Stern MB. Preclinical diagnosis of Parkinson's disease: are we there yet? Curr Neurol Neurosci Rep. 2006; 6: 295-301.
6. Hilker R, Schweitzer K, Coburger S, et al. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch Neurol. 2005; 62: 378-382.
7. Hawkes CH. The prodromal phase of sporadic Parkinson's disease: does it exist and if so how long is it? Mov Disord. 2008; 23: 1799-1807.
8. Marek K, Jennings D. Can we image premotor Parkinson disease? Neurology. 2009; 72( Suppl): S21-S26.
9. Marras C, Goldman S, Smith A. Smell identification ability in twin pairs discordant for Parkinson's disease. Mov Disord. 2005; 20: 687-693.
10. Savica R, Rocca WA, Ahlskog JE. When does Parkinson's disease start? Arch Neurol. 2010; 67: 798-801.
11. Ross GW, Petrovitch H, Abbott RD, et al. Association of olfactory dysfunction with risk for future Parkinson's disease. Ann Neurol. 2008; 63: 167-173.
12. Abbott RD, Ross GW, Petrovitch H, et al. Bowel movement frequency in late-life and incidental Lewy bodies. Mov Disord. 2007; 22: 1581-1586.
13. Schenck CH, Bundlie SR, Mahowald MW. Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology. 1996; 46: 388-393.
14. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003; 24: 197-211.
15. Lim SY, Fox SH, Lang AE. Overview of the extranigral aspects of Parkinson disease. Arch Neurol. 2009; 66: 167-172
16. Attems J, Jellinger KA. The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson's disease. Neuropathol Appl Neurobiol. 2008; 34: 466-467.
17. Braak H, de Vos RAI, Bohl J, Del Tredici K. Gastric alpha-synuclein ummunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci Lett. 2006; 396: 67-72.
18. Bloch A, Probst A, Bissig H, Adams H, Tolnay M. Alpha-synclein pathology of the spinal and peripheral autonomic nervous system in neurologically unimpaired elderly subjects. Neuropathol Appl Neurobiol. 2006; 32: 284-295.
19. Burke RE, Dauer W, Vonsattel JP. A critical evaluation of the Braak staging scheme for Parkinson's disease. Ann Neurol. 2008; 64: 485-491.
20. Dickson DW, Fujishiro H, DelleDonne A, et al. Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease. Acta Neuropathol. 2008; 115: 437-444.
21. Trojanowski JQ, Vandeerstchele H, Korecka M, et al. Update on the biomarker core of the Alzheimer's disease neuroimaging initiative subjects. Alzheimers Dement. 2010; 6: 230-238.
22. Polymeropoulos M, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997; 27: 2045-2047.
23. Shi M, Bradner J, Hancock AM, et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol. 2011; 69: 570-580.
24. Hong Z, Shi M, Chung KA, et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain. 2010; 133: 713-726.
25. Lesage S, Dürr A, Tazir M, et al; French Parkinson's Disease Genetics Study Group. LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. N Engl J Med. 2006; 354: 422-423.
26. Zhang J, Sokal I, Peskind ER, et al. CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol. 2008; 129: 526-529.
27. Gasser T. Genomic and proteomic biomarkers for Parkinson disease. Neurology. 2009; 72: S27-S31.
28. Shi M, Zabetian CP, Hancock AM, et al. Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease. Neurosci Lett. 2010; 480: 78-82.
29. Guo J, Sun Z, Xiao S, et al. Proteomic analysis of the cerebrospinal fluid of Parkinson's disease patients. Cell Res. 2009; 19: 1401-1403.
30. Goldknopf IL, Bryson JK, Strelets I, et al. Abnormal serum concentrations of proteins in Parkinson's disease. Biochem Biophys Res Commun. 2009; 389: 321-327.
31. Bogdanov M, Matson WR, Wang L, et al. Metabolomic profiling to develop blood biomarkers for Parkinson's disease. Brain. 2008; 131: 389-396.
32. Ahmed SS, Santosh W, Kumar S, Christlet HT. Metabolic profiling of Parkinson's disease: evidence of biomarker from gene expression analysis and rapid neural network detection. J Biomed Sci. 2009; 16: 63.
33. Berg D, Hochstrasser H, Schweitzer KJ, Riess O. Disturbance of iron metabolism in Parkinson's disease: ultrasonography as a biomarker. Neurotox Res. 2006; 9: 1-13.
34. Prestel J, Schweitzer KJ, Hofer A, et al. Predictive value of transcranial sonography in the diagnosis of Parkinson's disease. Mov Disord. 2006; 21: 1763-1765.
35. Sommer U, Hummel T, Cormann K, et al. Detection of presymptomatic Parkinson's disease: combining smell tests, transcranial sonography, and SPECT. Mov Disord. 2004; 19: 1196-1202.
36. Berg D, Seppi K, Behnkes S, et al. Enlarged substantia nigra hyperechogenicity and risk of Parkinson's disease: a 37 month 3-center study of 1847 older persons. Arch Neurol. 2011; 68: 932-937.
37. Panzacchi A, Moresco RM, Garibotto V, et al. A voxel-based PET study of dopamine transporters in Parkinson's disease: relevance of age at onset. Neurobiol Dis. 2008; 31: 102-109.
38. Ponsen MM, Stoffers D, Booij J, et al. Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann Neurol. 2004; 56: 173-181.
39. Piccini P, Burn DJ, Ceravolo R, et al. The role of inheritance in sporadic Parkinson's disease: evidence from a longitudinal study of dopaminergic function in twins. Ann Neurol. 1999; 45: 577-582.
40. Martin WR, Wieler M, Gee M. Midbrain iron content in early Parkinson disease: a potential biomarker of disease status. Neurology. 2008; 70: 1411-1417.
41. Peran P, Cherubini A, Assogna F, et al. Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature. Brain. 2010; 133: 3423-3433.
42. Vaillancourt DE, Spraker MB, Prodoehl J, et al. High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease. Neurology. 2009; 72: 1378-1384.
43. Scherfler C, Schocke MF, Seppi K, et al. Voxel-wise analysis of diffusion weighted imaging reveals disruption of the olfactory tract in Parkinson's Disease. Brain. 2006; 129: 538-542.
44. Rolheiser TM, Fulton HG, Good KP, et al. Diffusion tensor imaging and olfactory identification testing in early-stage Parkinson's disease. J Neurol. 2011; 258: 1254-1260.
45. Kikuchi A, Takeda A, Okamura, N, et al. In vivo visualization of alpha-synuclein deposition by carbon-11-labelled 2-[2-(2-dimethylaminothiazol-5-yl)ethenyl]-6-[2-(fluoro)ethoxy]benzoxazole positron emission tomography in multiple system atrophy. Brain. 2010; 133: 1772-1778.
46. Lang AE. A critical reappraisal of the premotor symptoms of Parkinson's disease: potential usefulness in early diagnosis and design of neuroprotective trials. Mov Disord. 2011; 26: 775-783.
47. Doty RL, Deems DA, Stellar S. Olfactory dysfunction in parkinsonism: a general deficit unrelated to neurologic signs, disease stage, or disease duration. Neurology. 1988; 38: 1237-1244.
48. Tissingh G, Berendse HW, Bergmans P, et al. Loss of olfaction in de novo and treated Parkinson's disease: possible implications for early diagnosis. Mov Disord. 2001; 16: 41-46.
49. Lebouvier T, Neunlist M, Bruley des Varannes S, et al. Colonic biopsies to assess the neuropathology of Parkinson's disease and its relationship with symptoms. PLoS One. 2010; 5: e12728.
50. Shannon KM, Keshavarzian A, Mutlu E, et al. Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease. Mov Disord. 2011 [Epub ahead of print].
51. Del Tredici K, Rub U, De Vos RA, Bohl JR, Braak H. Where does parkinson disease pathology begin in the brain? J Neuropathol Exp Neurol. 2002; 61: 413-426.
52. Braune S. The role of cardiac metaiodobenzylguanidine uptake in the differential diagnosis of parkinsonian syndromes. Clin Auton Res. 2001; 11: 351-355.
53. Orimo S, Uchihara T, Nakamura A, et al. Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease. Brain. 2008; 131: 642-650.
54. Orimo S, Takahashi A, Uchihara T, et al. Degeneration of cardiac sympathetic nerve begins in the early disease process of Parkinson's disease. Brain Pathol. 2007; 17: 24-30.
55. Okada Y, Ito Y, Aida J, Yasuhara M, Ohkawa S, Hirokawa K. Lewy bodies in the sinoatrial nodal ganglion: clinicopathological studies. Pathol Int. 2004; 54: 682-687.
56. Sauvageot N, Vaillant M, Diederich NJ. Reduced sympathetically driven heart rate variability during sleep in Parkinson's disease: a case control polysomnography-based study. Mov Disord. 2011; 26: 234-240.
57. Lanfranchi PA, Fradette L, Gagnon JF, et al. Cardiac autonomic regulation during sleep in idiopathic REM sleep behavior disorder. Sleep. 2007; 30: 1019-1025.
58. Iranzo A, Molinuevo JL, Santamaria J, et al. Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. Lancet Neurol. 2006; 5: 575-577.
59. Monderer R, Thorpy M. Sleep disorders and daytime sleepiness in Parkinson's disease. Curr Neurol Neurosci Rep. 2009; 9: 173-180.
60. Postuma RB, Gagnon JF, Vendette M, et al. Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology. 2009; 72: 1296-1300.
61. Iranzo A, Valldeoriola F, Lomena F, et al. Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behavior disorder: a prospective study. Lancet Neurol. 2011; 10: 797-805.
62. Postuma RB, Gagnon JF, Vendette M, et al. Olfaction and color vision identify impending neurodegeneration in rapid eye movement sleep behavior disorder. Ann Neurol. 2011; 69: 811-818.
63. Aarsland D, Brønnick K, Alves G, et al. The spectrum of neuropsychiatric symptoms in patients with early untreated Parkinson's disease. J Neurol Neurosurg Psychiatry. 2009; 80: 928-930.
64. Ishihara L, Brayne C. What is the evidence for a premorbid parkinsonian personality: a systematic review. Mov Disord. 2006; 21: 1066-1072.
65. Iranzo A, Lomena F, Stockner H, et al; Sleep Insnbruck Barcelona-SINBAR-group. Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idioapthic rapid-eye-movement sleep behaviour disorder: a prospective study. Lancet Neurol. 2010;: 1070-1077.